OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BYSI$1.4759

Beyondspring Inc

Biotechnology & Medical ResearchVerified

Beyondspring Inc operates with a negative equity position of $32.16 million and a cash and equivalents balance of $7.79 million, indicating a liquidity position that is constrained by its negative net worth. The company's market capitalization of $60.45 million is supported by a market price of $1.47 per share, with no dilution risk currently identified. The enterprise value to EBITDA ratio of -5.89 reflects the company's current unprofitable status and the challenges it faces in generating positive cash flows. The company's return on equity of 3.13% is modest, while its return on assets of -3.88% indicates that it is not effectively utilizing its assets to generate profit. These metrics are below the typical thresholds for a profitable biotechnology firm, suggesting that Beyondspring is in an early or development phase with limited revenue generation. Beyondspring's revenue is currently reported at $0, and its operating income is negative at $8.95 million, indicating that the company is not yet generating revenue from its operations and is incurring significant operating losses. The company's net income is also negative at $1.01 million, further emphasizing its unprofitable status. The company's capital expenditure of $50,000 is minimal, suggesting that it is not investing heavily in new projects or infrastructure at this time. The outlook for the current fiscal year indicates a continuation of the current trend, with no significant changes in revenue or expenses expected. The next fiscal year is also projected to maintain the current trajectory, with no substantial growth anticipated. The risk assessment for Beyondspring indicates a low liquidity risk, as the company has no immediate filing-based liquidity or dilution flags. However, the company's negative equity and operating cash flow of -$19.77 million suggest that it may face liquidity challenges in the future. The dilution risk is also assessed as low, with no immediate pressure for share issuance. Recent events, including the latest actual EPS of -$0.85 and revenue of $1.35 million, reflect the company's ongoing financial challenges. The ESG scores indicate a strong governance pillar with a score of 82.27, but a low social pillar score of 24.90 and a high ESG controversies score of 100.00, suggesting potential reputational risks.

30-day price · BYSI-0.11 (-6.9%)
Low$1.37High$1.84Close$1.49As of10 May, 00:00 UTC
Profile
CompanyBeyondspring Inc
TickerBYSI.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Beyondspring Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, primarily in the field of immuno-oncology.

Classification. Beyondspring is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.

Beyondspring Inc operates with a negative equity position of $32.16 million and a cash and equivalents balance of $7.79 million, indicating a liquidity position that is constrained by its negative net worth. The company's market capitalization of $60.45 million is supported by a market price of $1.47 per share, with no dilution risk currently identified. The enterprise value to EBITDA ratio of -5.89 reflects the company's current unprofitable status and the challenges it faces in generating positive cash flows. The company's return on equity of 3.13% is modest, while its return on assets of -3.88% indicates that it is not effectively utilizing its assets to generate profit. These metrics are below the typical thresholds for a profitable biotechnology firm, suggesting that Beyondspring is in an early or development phase with limited revenue generation. Beyondspring's revenue is currently reported at $0, and its operating income is negative at $8.95 million, indicating that the company is not yet generating revenue from its operations and is incurring significant operating losses. The company's net income is also negative at $1.01 million, further emphasizing its unprofitable status. The company's capital expenditure of $50,000 is minimal, suggesting that it is not investing heavily in new projects or infrastructure at this time. The outlook for the current fiscal year indicates a continuation of the current trend, with no significant changes in revenue or expenses expected. The next fiscal year is also projected to maintain the current trajectory, with no substantial growth anticipated. The risk assessment for Beyondspring indicates a low liquidity risk, as the company has no immediate filing-based liquidity or dilution flags. However, the company's negative equity and operating cash flow of -$19.77 million suggest that it may face liquidity challenges in the future. The dilution risk is also assessed as low, with no immediate pressure for share issuance. Recent events, including the latest actual EPS of -$0.85 and revenue of $1.35 million, reflect the company's ongoing financial challenges. The ESG scores indicate a strong governance pillar with a score of 82.27, but a low social pillar score of 24.90 and a high ESG controversies score of 100.00, suggesting potential reputational risks.
Key takeaways
  • Beyondspring Inc is a clinical-stage biopharmaceutical company with no current revenue and significant operating losses.
  • The company's financial position is characterized by negative equity and a constrained liquidity position.
  • The company's return on equity is modest, while its return on assets is negative, indicating inefficiency in asset utilization.
  • The company's capital expenditure is minimal, and the outlook for the next fiscal year does not indicate significant changes.
  • The risk assessment indicates low liquidity and dilution risks, but the company's negative operating cash flow suggests potential future liquidity challenges.
  • The ESG scores highlight a strong governance pillar but a weak social pillar and high controversies score.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$0.00
Gross profit
Operating income-$8.9M
Net income-$1.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$19.8M
CapEx-$50.0k
Free cash flow-$8.7M
Total assets$25.9M
Total liabilities$58.1M
Total equity-$32.2M
Cash & equivalents$7.8M
Long-term debt$0.00
Valuation
Market price$1.47
Market cap$60.4M
Enterprise value$52.7M
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$32.2M
Net cash$7.8M
Current ratio1.5
Debt/Equity-0.0
ROA-3.9%
ROE3.1%
Cash conversion19.6%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricBYSIActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity-0.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Observations
IR observations
Last actual EPS-0.85 USD
Last actual revenue1,351,000 USD
Social pillar24.90 (0-100)
Governance pillar82.27 (0-100)
ESG controversies score100.00 (0-100, higher = fewer controversies)
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 16:22 UTC#ed7ead7d
Market quoteclose USD 1.42 · shares 0.04B diluted
no public URL
2026-05-16 16:24 UTC#498d4aef
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 14:12 UTCJob: f199431e